Format

Send to

Choose Destination
Diabetologia. 2008 May;51(5):703-13. doi: 10.1007/s00125-008-0936-9. Epub 2008 Mar 4.

Beta cell mass in diabetes: a realistic therapeutic target?

Author information

1
Department of Medicine I, St Josef-Hospital, Ruhr-University of Bochum, Gudrunstr. 56, 44791, Bochum, Germany. juris.meier@rub.de

Abstract

Beta cell deficiency underlies both type 1 and type 2 diabetes, and restoration or replacement of beta cell function is therefore the logical long-term solution to therapy. This review sets out to describe the defects in beta cell mass and function in both forms of diabetes, summarises current understanding of the underlying causes of beta cell death, and the methodological limitations of determining beta cell mass in vivo. Finally, the potential effects of current and future treatment regimens on beta cell mass and turnover are considered.

PMID:
18317728
DOI:
10.1007/s00125-008-0936-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center